Evolus (EOLS) AI Stock Analysis

• Market Cap: $456.33M
• Dividend Yield: N/A
• Average Volume (3M): 1.58M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 15.10%
• EPS Growth: 0.18%
• Country: US
• Employees: 372
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.13
• Shares Outstanding: 64,819,786
• 10 Day Avg. Volume: 1,443,697
• 30 Day Avg. Volume: 1,582,818
• PEG Ratio: 0.54
• Price to Book (P/B): 123.99
• Price to Sales (P/S): 2.57
• P/FCF Ratio: -35.16
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 1.78
• Enterprise Value/Gross Profit: 2.70
• Enterprise Value/Ebitda: -17.36
• 1Y Price Target: $19.50
• Price Target Upside: 176.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -0.5
• Revenue Forecast (FY): $298.52M

• Rating: 49 Neutral
• Price Target: $7.00 ▼(-0.57% Downside)

Evolus' overall stock score is primarily influenced by its financial performance challenges, including high leverage and negative equity. However, the positive sentiment from the earnings call, driven by strong consumer engagement and strategic initiatives, provides a counterbalance. Technical indicators and valuation metrics suggest moderate to low attractiveness, with ongoing profitability issues being a significant concern.

Positive Factors

Revenue Growth

The 13% revenue growth in Q3 indicates strong demand for Evolus' products, suggesting a robust market position and potential for continued expansion.

Product Launch Success

The successful launch of Evolysse, with significant revenue generation, strengthens Evolus' product portfolio and enhances its competitive edge in the aesthetic market.

International Market Expansion

Expansion into new international markets, particularly the U.K., demonstrates Evolus' strategic growth initiatives and potential for increased global market share.

Negative Factors

High Leverage

High leverage and negative equity pose significant financial risks, potentially limiting Evolus' ability to invest in growth and manage economic downturns.

Profitability Challenges

Persistent profitability issues highlight cost management challenges, which could hinder long-term financial stability and growth potential.

Tariff Uncertainty

Tariff uncertainties could impact product costs and pricing strategies, affecting Evolus' competitive positioning and profitability in key markets.

Evolus Business Overview & Revenue Model

Company Description

Evolus, Inc. is a performance-based aesthetic company focused on delivering innovative, non-surgical aesthetic solutions to enhance beauty and confidence. The company primarily operates in the medical aesthetics sector and offers products designed to address the needs of consumers and healthcare providers. Evolus is known for its flagship product, Jeuveau, a botulinum toxin type A injectable treatment aimed at reducing the appearance of glabellar lines, commonly known as frown lines. The company focuses on providing advanced aesthetic technologies that cater to a growing market of consumers seeking non-invasive aesthetic treatments.

How the Company Makes Money

Evolus generates revenue primarily through the sale of its aesthetic products, with Jeuveau being its main source of income. The company employs a business model that includes direct sales to licensed healthcare professionals and partnerships with aesthetic clinics. Revenue is driven by product sales and the establishment of distribution agreements with various medical aesthetic providers. Additionally, Evolus invests in marketing and promotional campaigns to raise awareness of its products among consumers and practitioners, further enhancing its sales potential. The company's focus on innovation and the expansion of its product portfolio plays a significant role in driving revenue growth and sustaining its competitive edge in the market.

Evolus Financial Statement Overview

Summary

Evolus is experiencing revenue growth, but profitability and financial stability remain significant challenges. The high leverage and negative equity pose risks, while cash flow improvements offer a glimmer of hope. Overall, the company needs to address its cost structure and financial leverage to improve its financial health.

Income Statement

Evolus has shown some revenue growth with a TTM increase of 2.84%, but profitability remains a challenge. The company has a negative net profit margin of -22.34% and an EBIT margin of -15.60%, indicating ongoing operational losses. Despite a decent gross profit margin of 66.73%, the negative margins highlight significant cost management issues.

Balance Sheet

The balance sheet reveals a concerning financial structure with a negative stockholders' equity and a high debt-to-equity ratio of -8.31 in TTM, indicating high leverage and financial instability. Although the return on equity is positive at 17.91%, it is primarily due to the negative equity, which is a risk factor.

Cash Flow

Cash flow analysis shows a significant improvement in free cash flow growth at 85.26% TTM, yet the company still faces negative operating cash flow. The free cash flow to net income ratio is slightly above 1, suggesting some efficiency in cash management despite ongoing losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	285.82M	266.27M	202.09M	148.62M	99.67M	56.54M
Gross Profit	188.16M	182.30M	140.53M	89.77M	56.14M	38.24M
EBITDA	-29.31M	-25.00M	-41.81M	-53.85M	-39.06M	-144.75M
Net Income	-58.56M	-50.42M	-61.69M	-74.41M	-46.81M	-163.01M
Balance Sheet
Total Assets	219.00M	232.57M	189.00M	177.98M	257.48M	209.07M
Cash, Cash Equivalents and Short-Term Investments	43.52M	86.95M	62.84M	53.92M	146.26M	107.56M
Total Debt	154.89M	129.98M	126.55M	74.42M	74.74M	138.32M
Total Liabilities	247.76M	227.05M	209.69M	159.48M	175.61M	282.03M
Stockholders Equity	-28.76M	5.52M	-20.69M	18.50M	81.88M	-72.96M
Cash Flow
Free Cash Flow	-56.35M	-19.47M	-35.63M	-87.85M	-34.36M	-61.01M
Operating Cash Flow	-50.28M	-18.00M	-34.01M	-84.91M	-33.39M	-57.87M
Investing Cash Flow	-7.65M	-4.82M	-1.63M	-2.94M	4.03M	12.19M
Financing Cash Flow	15.95M	47.41M	44.64M	-4.15M	73.05M	38.35M

Evolus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EOLS, the sentiment is Positive. The current price of 7.04 is above the 20-day moving average (MA) of 6.87, above the 50-day MA of 6.60, and below the 200-day MA of 9.28, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 53.79 is Neutral, neither overbought nor oversold. The STOCH value of 35.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EOLS.

Evolus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EBS	69 Neutral	$586.65M	8.63	13.92%	―	-29.91%	―
ORGO	60 Neutral	$687.86M	―	0.30%	―	2.24%	-67.56%
DERM	57 Neutral	$212.47M	―	-47.05%	―	2.82%	60.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EOLS	49 Neutral	$456.33M	―	―	―	15.10%	0.18%
RMTI	41 Neutral	$36.84M	―	-16.67%	―	-23.60%	-179.33%
AQST	41 Neutral	$758.86M	―	―	―	-26.32%	-56.54%

Evolus Corporate Events

Evolus, Inc. Earnings Call Highlights Growth and Resilience

Evolus, Inc. Earnings Call Reflects Resilience Amidst Growth and Challenges

Evolus, Inc. Reports Strong Q3 2025 Growth

Evolus, Inc. is a global performance beauty company specializing in aesthetic injectables, with a focus on consumer-centric products and innovative digital platforms. The company is known for its flagship products, Jeuveau® and Evolysse™, which are designed to redefine the aesthetic injectable market.

Evolus Appoints Tatjana Mitchell as New CFO

On September 8, 2025, Evolus, Inc. announced the appointment of Tatjana Mitchell as its new Chief Financial Officer. With over 20 years of experience in strategic and operational finance, Mitchell is expected to play a crucial role in driving revenue growth and operational excellence as Evolus expands its portfolio and global footprint. Her previous roles include Senior Vice President of Corporate Finance at Experian and CFO at Zulily, where she demonstrated a strong track record in financial management and strategic execution.

The most recent analyst rating on (EOLS) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.